InMode (NASDAQ:INMD) Updates FY25 Earnings Guidance

InMode (NASDAQ:INMD) updated its FY25 earnings guidance on Tuesday. The company provided earnings per share guidance of $1.95-$1.99 for the period, compared to the consensus earnings per share estimate of $1.98. The company issued revenue guidance of $395-$405 million, compared to the consensus revenue estimate of $413.47 million.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Barclays boosted their price target on shares of InMode from $26.00 to $29.00 and gave the stock an “overweight” rating in a report on Wednesday. BTIG Research assumed coverage on shares of InMode in a report on Thursday, October 17th. They set a “buy” rating and a $25.00 price target for the company. Finally, Needham & Company LLC reiterated a “hold” rating on shares of InMode in a report on Tuesday. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $23.00.

InMode Stock Performance

InMode stock traded up $0.11 during trading hours on Thursday, reaching $18.07. 141,062 shares of the stock were exchanged, compared to its average volume of 868,796. InMode has a 52-week low of $14.87 and a 52-week high of $26.80. The stock has a market cap of $1.52 billion, a P/E ratio of 9.77 and a beta of 2.13. The firm’s 50 day moving average is $17.41 and its 200 day moving average is $17.20.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.